Antibodies to interleukin 12 abrogate established experimental colitis in mice - PubMed (original) (raw)

Antibodies to interleukin 12 abrogate established experimental colitis in mice

M F Neurath et al. J Exp Med. 1995.

Abstract

In this study, we describe a novel murine model of chronic intestinal inflammation induced by the hapten reagent 2,4,6-trinitrobenzene sulfonic acid (TNBS). Rectal application of low doses of TNBS in BALB/c and SJL/J mice resulted in a chronic transmural colitis with severe diarrhea, weight loss, and rectal prolapse, an illness that mimics some characteristics of Crohn's disease in humans. The colon of TNBS-treated mice on day 7 was marked by infiltration of CD4+ T cells; furthermore, in situ polymerase chain reaction studies revealed high levels of interferon (IFN)-gamma mRNA in diseased colons. Isolated lamina propria (LP) CD4+ T cells from TNBS-treated mice stimulated with anti-CD3 and anti-CD28 antibodies exhibited a Th1 pattern of cytokine secretion: a 20-50-fold increase in IL-2 and IFN-gamma levels and a 5-fold decrease in IL-4 levels as compared with those of stimulated LP CD4+ T cells from control BALB/c mice. Administration of monoclonal anti-IL-12 antibodies to the TNBS-treated mice both early (at 5 d) and late (at 20 d) after induction of colitis led to a striking improvement in both the clinical and histopathological aspects of the disease and frequently abrogated the established colitis completely. Furthermore, LP CD4+ T cells isolated from anti-IL-12-treated mice failed to secrete IFN-gamma upon in vitro stimulation. In summary, the data demonstrate the pivotal role of IL-12 and IFN-gamma in a TNBS-induced murine model of chronic intestinal inflammation. Furthermore, they suggest the potential utility of anti-IL-12 antibodies in patients with Crohn's disease.

PubMed Disclaimer

Similar articles

• Tolerance towards resident intestinal flora in mice is abrogated in experimental colitis and restored by treatment with interleukin-10 or antibodies to interleukin-12.
  Duchmann R, Schmitt E, Knolle P, Meyer zum Büschenfelde KH, Neurath M. Duchmann R, et al. Eur J Immunol. 1996 Apr;26(4):934-8. doi: 10.1002/eji.1830260432. Eur J Immunol. 1996. PMID: 8625991
• Evidence for the critical role of interleukin-12 but not interferon-gamma in the pathogenesis of experimental colitis in mice.
  Tozawa K, Hanai H, Sugimoto K, Baba S, Sugimura H, Aoshi T, Uchijima M, Nagata T, Koide Y. Tozawa K, et al. J Gastroenterol Hepatol. 2003 May;18(5):578-87. doi: 10.1046/j.1440-1746.2003.03024.x. J Gastroenterol Hepatol. 2003. PMID: 12702051
• Oral administration of recombinant cholera toxin subunit B inhibits IL-12-mediated murine experimental (trinitrobenzene sulfonic acid) colitis.
  Boirivant M, Fuss IJ, Ferroni L, De Pascale M, Strober W. Boirivant M, et al. J Immunol. 2001 Mar 1;166(5):3522-32. doi: 10.4049/jimmunol.166.5.3522. J Immunol. 2001. PMID: 11207312
• Preclinical Study in Vivo for New Pharmacological Approaches in Inflammatory Bowel Disease: A Systematic Review of Chronic Model of TNBS-Induced Colitis.
  Silva I, Pinto R, Mateus V. Silva I, et al. J Clin Med. 2019 Oct 1;8(10):1574. doi: 10.3390/jcm8101574. J Clin Med. 2019. PMID: 31581545 Free PMC article. Review.
• Inflammatory Bowel Disease: A Review of Pre-Clinical Murine Models of Human Disease.
  Katsandegwaza B, Horsnell W, Smith K. Katsandegwaza B, et al. Int J Mol Sci. 2022 Aug 19;23(16):9344. doi: 10.3390/ijms23169344. Int J Mol Sci. 2022. PMID: 36012618 Free PMC article. Review.

Cited by

• Deletion of interleukin (IL)-12p35 induces liver fibrosis in dominant-negative TGFβ receptor type II mice.
  Tsuda M, Zhang W, Yang GX, Tsuneyama K, Ando Y, Kawata K, Park O, Leung PS, Coppel RL, Ansari AA, Ridgway WM, Gao B, Lian ZX, Flavell R, He XS, Gershwin ME. Tsuda M, et al. Hepatology. 2013 Feb;57(2):806-16. doi: 10.1002/hep.25829. Hepatology. 2013. PMID: 22576253 Free PMC article.
• Cytokines: From Clinical Significance to Quantification.
  Liu C, Chu D, Kalantar-Zadeh K, George J, Young HA, Liu G. Liu C, et al. Adv Sci (Weinh). 2021 Aug;8(15):e2004433. doi: 10.1002/advs.202004433. Epub 2021 Jun 10. Adv Sci (Weinh). 2021. PMID: 34114369 Free PMC article. Review.
• Distinct profiles of effector cytokines mark the different phases of Crohn's disease.
  Zorzi F, Monteleone I, Sarra M, Calabrese E, Marafini I, Cretella M, Sedda S, Biancone L, Pallone F, Monteleone G. Zorzi F, et al. PLoS One. 2013;8(1):e54562. doi: 10.1371/journal.pone.0054562. Epub 2013 Jan 17. PLoS One. 2013. PMID: 23349929 Free PMC article.
• Nisin lantibiotic prevents NAFLD liver steatosis and mitochondrial oxidative stress following periodontal disease by abrogating oral, gut and liver dysbiosis.
  Kuraji R, Ye C, Zhao C, Gao L, Martinez A, Miyashita Y, Radaic A, Kamarajan P, Le C, Zhan L, Range H, Sunohara M, Numabe Y, Kapila YL. Kuraji R, et al. NPJ Biofilms Microbiomes. 2024 Jan 17;10(1):3. doi: 10.1038/s41522-024-00476-x. NPJ Biofilms Microbiomes. 2024. PMID: 38233485 Free PMC article.
• The translation of non-canonical open reading frames controls mucosal immunity.
  Jackson R, Kroehling L, Khitun A, Bailis W, Jarret A, York AG, Khan OM, Brewer JR, Skadow MH, Duizer C, Harman CCD, Chang L, Bielecki P, Solis AG, Steach HR, Slavoff S, Flavell RA. Jackson R, et al. Nature. 2018 Dec;564(7736):434-438. doi: 10.1038/s41586-018-0794-7. Epub 2018 Dec 12. Nature. 2018. PMID: 30542152 Free PMC article.

References

1. 1. Immunology. 1993 Jan;78(1):127-31 - PubMed
2. 1. Arch Biochem Biophys. 1992 Apr;294(1):230-7 - PubMed
3. 1. Cell. 1993 Oct 22;75(2):203-5 - PubMed
4. 1. Cell. 1993 Oct 22;75(2):253-61 - PubMed
5. 1. Cell. 1993 Oct 22;75(2):263-74 - PubMed

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Europe PubMed Central
  • Ovid Technologies, Inc.
  • PubMed Central
  • Silverchair Information Systems

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information

• Research Materials

  • NCI CPTC Antibody Characterization Program